Purchase Short-Term Access

Review: Tamoxifen, raloxifene, and tibolone prevent primary invasive breast cancer but increase risk for adverse outcomes

Joy Melnikow, MD, MPH

Annals of Internal Medicine 2010;152:JC3-4. doi:10.7326/0003-4819-152-6-201003160-02004

Purchase Online access to this article for 24 hours

Annals of Internal Medicine

Forgot Your Password?

to gain full access to the content and tools.

Learn more about subscription options

Forgot your password?

Enter your username and email address. We'll send you a reminder to the email address on record.

Username* (Required)

Email Address* (Required)